SEC 13F Intelligence

Managers / Q3 2019 · view latest →

Camber Capital Management LP

CIK 0001444043 · 101 HUNTINGTON AVENUE, SUITE 2101, BOSTON, MA, 02199 · 617-717-6600

Reported Value
$1.9B
Q3 2019
Positions
34
Filings on Record
28
2019–present window
Filed
Nov 14, 2019
original filing

Summary

Camber Capital Management LP reported $1.9B in U.S.-listed holdings across 34 positions for Q3 2019.

Its largest position, Allergan, represents 8.8% of the portfolio.

Compared with Q2 2019, the fund opened 8 new positions and exited 5.

Portfolio Metrics

Turnover
+21.1%
vs prior filed quarter
Top-10 Concentration
+52.5%
share of reported value
Largest Position
+8.8%
Allergan
New / Exited
8 / 5
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $2.1BQ4 ’18Q1 ’19: $2.0BQ2 ’19: $2.1BQ3 ’19: $1.9BQ4 ’19: $2.0BQ4 ’19Q1 ’20: $1.7BQ2 ’20: $1.7BQ3 ’20: $1.9BQ4 ’20: $2.8BQ4 ’20Q1 ’21: $2.9BQ2 ’21: $3.0BQ3 ’21: $3.2BQ4 ’21: $2.9BQ4 ’21Q1 ’22: $2.8BQ2 ’22: $2.3BQ3 ’22: $3.3BQ1 ’23: $3MQ1 ’23Q2 ’23: $3MQ3 ’23: $3MQ4 ’23: $4MQ1 ’24: $4MQ1 ’24Q2 ’24: $4MQ3 ’24: $3MQ4 ’24: $4MQ2 ’25: $1.1BQ2 ’25filingsflow.com

Portfolio Composition

By security type
Common Stock: 56.0%Other: 42.1%ADR: 1.9%
  • Common Stock · 56.0% · $1.1B
  • Other · 42.1% · $800M
  • ADR · 1.9% · $36M

Quarter-over-Quarter Changes full breakdown →

vs Q2 2019 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
BIIBBIOGEN INCNEW+350.0K350.0K+$81M$81M
ABBVABBVIE INCNEW+500.0K500.0K+$38M$38M
NVONOVO-NORDISK A SNEW+700.0K700.0K+$36M$36M
MYGNMYRIAD GENETICS INCNEW+1.00M1.00M+$29M$29M
WRIGHT MED GROUP N VNEW+750.0K750.0K+$15M$15M
GLYCEURGLYCOMIMETICS INCNEW+3.50M3.50M+$15M$15M
TRANSLATE BIO INCNEW+1.50M1.50M+$15M$15M
AVROBIO INCNEW+500.0K500.0K+$7M$7M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2019

32 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1ALLERGAN PLCSHS8.85%$168M1.00M
2MYLAN N VSHS EURO8.84%$168M8.50M
3PERRIGO CO PLCSHS5.00%$95M1.70M
4B7SBROOKDALE SENIOR LIVINGhistory →COM4.98%$95M12.50M
5TRLDAVITA INChistory →COM4.50%$86M1.50M
6ALXNALEXION PHARMACEUTICALS INChistory →COM4.38%$83M850.0K
7BIIBBIOGEN INChistory →COM4.29%$81M350.0K
8BMYBRISTOL MYERS SQUIBB COhistory →COM4.00%$76M1.50M
9UHSUNIVERSAL HLTH SVCS INChistory →CL B3.91%$74M500.0K
10HCAHCA HEALTHCARE INChistory →COM3.80%$72M600.0K
11THCTENET HEALTHCARE CORPhistory →COM NEW3.66%$70M3.15M
12ALKERMES PLCSHS3.59%$68M3.50M
13ASCENDIS PHARMA A SSPONSORED ADR3.29%$63M650.0K
14SRPTSAREPTA THERAPEUTICS INChistory →COM2.97%$56M750.0K
15NKTREURNEKTAR THERAPEUTICShistory →COM2.87%$55M3.00M
16AMAGAMAG PHARMACEUTICALS INChistory →COM2.67%$51M4.39M
17MNTAMOMENTA PHARMACEUTICALS INChistory →COM2.39%$45M3.50M
18ATRAGBXATARA BIOTHERAPEUTICS INChistory →COM2.19%$42M2.95M
19ABBVABBVIE INChistory →COM1.99%$38M500.0K
20ZYMEUSDZYMEWORKS INChistory →COM1.96%$37M1.50M
21NVONOVO-NORDISK A Shistory →ADR1.90%$36M700.0K
22UTHUNITED THERAPEUTICS CORP DELhistory →COM1.68%$32M400.0K
23SYNTHORX INCCOM1.59%$30M1.86M
24MYGNMYRIAD GENETICS INChistory →COM1.51%$29M1.00M
25CYCNUSDCYCLERION THERAPEUTICS INChistory →COM1.42%$27M2.23M
26GLAXOSMITHKLINE PLCSPONSORED ADR1.12%$21M500.0K
27WRIGHT MED GROUP N VORD SHS0.81%$15M750.0K
28GLYCEURGLYCOMIMETICS INChistory →COM0.79%$15M3.50M
29TRANSLATE BIO INCCOM0.78%$15M1.50M
30AVROBIO INCCOM0.37%$7M500.0K
31SUTRO BIOPHARMA INCCOM0.29%$5M600.0K
32SGRYSURGERY PARTNERS INCCOM0.06%$1M160.1K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q2 2025$1.1B25Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025Under review32May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$4M39Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$3M33Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$4M37Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$4M36May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$4M38Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$3M40Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$3M38Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$3M41May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022Under review39Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$3.3B45Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$2.3B40Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$2.8B37May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$2.9B39Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$3.2B39Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$3.0B34Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$2.9B32May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$2.8B33Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$1.9B35Nov 16, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$1.7B30Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$1.7B29May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$2.0B29Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$1.9B34Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$2.1B31Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$2.0B28May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$2.1B36Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.